INmune Bio, Inc.
General ticker "INMB" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $70.7M (TTM average)
INmune Bio, Inc. does not follow the US Stock Market performance with the rate: -26.4%.
Estimated limits based on current volatility of 3.1%: low 1.35$, high 1.43$
Factors to consider:
- Total employees count: 10 as of 2022
- Top business risk factors: Significant losses, FDA clinical hold, Need for additional capital, Liquidity and credit risks, Dependence on key products
- Price in estimated range
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [0.97$, 3.33$]
- 2026-12-31 to 2027-12-31 estimated range: [1.29$, 4.00$]
Financial Metrics affecting the INMB estimates:
- Positive: with PPE of -1.5 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Shareholder equity ratio, % of 72.71 > 64.29
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: -4.41 < Investing cash flow per share per price, % of -2.26
Short-term INMB quotes
Long-term INMB plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.15MM | $0.01MM | $0.05MM |
| Operating Expenses | $29.90MM | $42.65MM | $47.43MM |
| Operating Income | $-29.74MM | $-42.63MM | $-47.38MM |
| Non-Operating Income | $-0.27MM | $0.55MM | $1.45MM |
| R&D Expense | $20.27MM | $33.17MM | $20.66MM |
| Income(Loss) | $-30.01MM | $-42.08MM | $-45.93MM |
| Net Income(Loss)* | $-30.01MM | $-42.08MM | $-45.93MM |
| Stockholders Equity | $37.34MM | $32.10MM | $23.52MM |
| Assets | $57.00MM | $39.56MM | $32.35MM |
| Operating Cash Flow | $-11.98MM | $-33.36MM | $-22.58MM |
| Capital expenditure | $0.00MM | $0.00MM | $1.04MM |
| Investing Cash Flow | $0.00MM | $0.00MM | $-1.04MM |
| Financing Cash Flow | $-4.22MM | $18.21MM | $27.61MM |
| Earnings Per Share** | $-1.67 | $-2.11 | $-1.73 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.